
3

33

40 3 33 ß % positive wells ဗ္တ % positive wells Figure 1. Stimulatory potential of CM in PBMC from healthy donors 8 8 5 8 5 **9** . 9 S AEKY10 AEKY10-DR2a GA-TCC-210 GA-TCC-110 **AEKY10-DR2b** AEKY10 GA-100-110 GA-700-210 AEKY10-DR20 AEKY10 DR2a 32 45 40 30 33 35 % positive wells ಜ % positive wells . 82 32 5 20 15 10 10 Ŋ AEKY20 AEKY15 AEKY12 Non-Ac AEKY 15 θ AEKY106A AEKY10 AEKY20 AEKY12 AEKY15 AEKY10 ₽ B Non-Ac AEKY 15 **AEKY10-GA** A 2

Figure 2. Stimulatory potential of CM in PBMC from MS patients

A








Figure 3. SJL spleen primary proliferative responses to CM




Figure 4. Cross reactivity of CM-specific mouse T cell lines to myelin




Figure 5. CM reduce clinical severity in PLP₁₃₉₋₁₅₁-induced EAE

